{
  "id": "602826da1cb411341a0000fb",
  "type": "list",
  "question": "What are the targets of pemigatinib?",
  "ideal_answer": "Pemigatinib is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) 1, FGFR2 and FGFR3, received accelerated approval  for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and a FGFR2 fusion or other rearrangement, as detected by a US FDA-approved test.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32684989",
    "http://www.ncbi.nlm.nih.gov/pubmed/32677452",
    "http://www.ncbi.nlm.nih.gov/pubmed/32203698",
    "http://www.ncbi.nlm.nih.gov/pubmed/32472305",
    "http://www.ncbi.nlm.nih.gov/pubmed/32315352"
  ],
  "snippets": [
    {
      "text": "Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32203698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pemigatinib (PEMAZYRE\u2122), a small molecule inhibitor of fibroblast growth factor receptor (FGFR) 1, FGFR2 and FGFR3, received accelerated approval in April 2020 in the USA for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma and a FGFR2 fusion or other rearrangement, as detected by a US FDA-approved test. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32472305",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315352",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we present the molecular structure and preclinical characterization of INCB054828 (pemigatinib), a novel, selective inhibitor of FGFR 1, 2, and 3, currently in phase 2 clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315352",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pemigatinib, a selective, potent, oral inhibitor of FGFR1-3, has demonstrated efficacy and safety in a Phase II study of patients with previously treated locally advanced/metastatic CCA harboring FGFR2 fusions/rearrangements.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32677452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32684989",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " we present the molecular structure and preclinical characterization of INCB054828 (pemigatinib), a novel, selective inhibitor of FGFR 1, 2, and 3, currently in phase 2 clinical trials. INCB054828",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315352",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "is disease. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3.Methods: The FiGhTeR trial is a phase II, single-arm, open-label study to assess safety and activity of the FGFR inhibitor pemigatinib as second-line treatment strategy in metastatic EGJ/GC patients progressing under trastuzumab-",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32684989",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we present the molecular structure and preclinical characterization of INCB054828 (pemigatinib), a novel, selective inhibitor of FGFR 1, 2, and 3, currently in phase 2 clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32315352",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "FGFR 1, FGFR2, FGFR3"
}